

UDC 547.79

I. I. Myrko

Danylo Halytsky Lviv National Medical University, 69 Pekarska str., 79010 Lviv, Ukraine

Synthesis and Anti-inflammatory Activity of Some New 6-Aryltriazolo[3,4-*b*][1,3,4]thiadiazole Derivatives

Abstract

A series of 6-aryl[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole derivatives has been synthesized. Their anti-inflammatory activity has been studied *in vivo* in a carrageenan model of the paw inflammatory edema in rats. 3-(2-Fluorophenyl)-6-phenyl-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (**3c**) and 3-(2-fluorophenyl)-6-(4-methoxy-phenyl)[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (**3d**) have been identified as hit compounds with the anti-exudative activity. The crucial role of the fluorine atom in the anti-inflammatory activity has been determined, which value considerably correlates with the calculated values of lipophilicity and solubility.

Keywords: [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole; anti-inflammatory activity; cyclooxygenase; docking

I. I. Мирко

Львівський національний медичний університет імені Данила Галицького,
вул. Пекарська, 69, м. Львів, 79010, Україна

Синтез та протизапальна активність деяких нових похідних 6-арил[1,2,4]триазоло[3,4-*b*][1,3,4]тіадіазолу

Анотація

Синтезовано ряд похідних 6-арил[1,2,4]триазоло[3,4-*b*][1,3,4]тіадіазолу. Для цих сполук досліджено *in vivo* протизапальну активність на карагеніновій моделі запального набряку лапи щура. 3-(2-Фторофеніл)-6-феніл-[1,2,4]триазоло[3,4-*b*][1,3,4]тіадіазол (**3c**) та 3-(2-фторофеніл)-6-(4-метоксифеніл)[1,2,4]триазоло[3,4-*b*][1,3,4]тіадіазол (**3d**) було ідентифіковано як сполуки-хіти з антиексудативною активністю. Виявлено важливу роль атома Фтору в протизапальній активності, величина якої корелює з розрахованими значеннями ліпофільності та розчинності.

Ключові слова: [1,2,4]триазоло[3,4-*b*][1,3,4]тіадіазол; протизапальна активність; циклооксигеназа; докінг

Citation: Myrko, I. I. Synthesis and anti-inflammatory activity of some new 6-aryltriazolo[3,4-*b*][1,3,4]thiadiazole derivatives. *Journal of Organic and Pharmaceutical Chemistry* **2024**, *22* (4), 17–24.

<https://doi.org/10.24959/ophcj.24.321751>

Received: 115 September 2024; **Revised:** 1 December 2024; **Accepted:** 5 December 2024

Copyright © 2024, I. I. Myrko. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0>).

Funding: The author received no specific funding for this work.

Conflict of interests: The author has no conflict of interests to declare.

■ Introduction

Inflammation is a universal physiological response to injury that can be caused by infectious, allergic, toxic, physical, and neurogenic factors. It is one of the most common diseases that can be fatal [1]. Nonsteroidal anti-inflammatory drugs (NSAIDs) represent a class of important therapeutic agents. They are used as anti-inflammatory, antipyretic, and analgesic medicines. However, NSAIDs may cause serious side effects, including gastrointestinal bleeding, peptic ulcer disease, hypertension, edema, and kidney disease [2].

Some NSAIDs have also been associated with an increased risk of myocardial infarction [3]. Therefore, novel anti-inflammatory and analgesic compounds with improved safety profiles still need to be invented.

Currently, the synthesis and biological activities of various 1,2,4-triazole and 1,3,4-thiadiazole derivatives and their *N*-bridged heterocyclic analogs are the subject of intensive research [4–7]. 1,2,4-Triazole and 1,3,4-thiadiazole rings are known to be unique pharmacophores in several drugs and natural products. The favorable properties of triazole and thiadiazole rings, including

moderate dipole properties, hydrogen bonding ability, optimal lipophilicity and rigidity, are responsible for their biological activities [4–7]. Thiadiazole is the bioisostere of pyrimidine and oxadiazole [7].

[1,2,4]Triazolo[3,4-*b*][1,3,4]thiadiazoles, including 1,2,4-triazole and 1,3,4-thiadiazole rings, are attractive heterocyclic compounds for medical chemists. They are important analogs of bioactive compounds with diverse pharmacological effects, including the anti-inflammatory one [8–18]. Among [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole derivatives, some selective inhibitors of the cyclooxygenase COX-2 isoform were found [18, 19].

The aim of this work was to synthesize new [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole derivatives and study their anti-exudative potential.

Results and discussion

Synthesis of [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole targeted derivatives


The synthesis of the targeted [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole derivatives was carried out by the reaction of 1-amino-4-*H*-[1,2,4]triazol-

3-thiols **1a–c** with commercially available benzoic acid **2a** and its substituted derivatives **2b–d** (Scheme). The reaction was performed in POCl₃ under reflux. The resulting compounds are light yellow substances that are highly soluble in DMFA, DMSO, and dioxane, moderately soluble in ethanol and acetic acid, and insoluble in water and non-polar solvents.

The anti-inflammatory activity of compounds **3a–f** synthesized was evaluated by the carrageenan-induced paw edema method [19]. The compounds were tested in the dose of 50 mg kg⁻¹, and the activity was compared to the reference drugs – Ibuprofen, Diclofenac, and Ketorolac in the mean therapeutic dose of 10 mg kg⁻¹ (Table 1).

Compounds **3c** and **3d** were identified as the most active among the substances studied, and their anti-inflammatory effect was equal to or higher than that of the reference drugs. A significant effect was also observed in the case of compound **3b**. All active compounds possess a fluorine atom in the aromatic cycle in position 6 of the [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole moieties.

Compounds containing heterocyclic rings substituted with fluorinated phenyl moiety are



1a: R = C₆H₅; **1b:** R = 2-F-C₆H₄; **1c:** R = 4-Cl-C₆H₄CH₂; **1d:** R = 4-MeO-C₆H₄CH₂

2a: R¹ = H; **2b:** R¹ = 4-CF₃; **2c:** R¹ = 4-MeO; **2d:** R¹ = 3,4-*di*-MeO

3a: R = C₆H₅, R¹ = H; **3b:** R = C₆H₅, R¹ = 4-CF₃; **3c:** R = 2-F-C₆H₄, R¹ = H;

3d: R = 2-F-C₆H₄, R¹ = 4-MeO; **3e:** R = 4-Cl-C₆H₄CH₂, R¹ = H;

3f: R = 4-MeO-C₆H₄CH₂, R¹ = 3,4-*di*-MeO

Scheme. The synthesis of [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazoles **3a–f**

Table 1. The anti-inflammatory activity of compounds **3a–f** synthesized compared to Ibuprofen, Diclofenac and Ketorolac

Compound	Paw edema volume, (mL) ± SEM*	Inhibition, %	Activity relative to Ibuprofen, %	Activity relative to Diclofenac, %	Activity relative to Ketorolac, %
Control	2.20 ± 0.05	-	-	-	-
3a	1.73 ± 0.04	21.4	53.5	49.1	55.4
3b	1.48 ± 0.05	32.7	81.8	75.0	84.7
3c	1.24 ± 0.03	43.6	109.0	100.0	113.0
3d	1.27 ± 0.05	42.3	105.8	97.0	109.6
3e	1.64 ± 0.02	25.5	63.8	58.5	66.1
3f	1.94 ± 0.03	11.8	29.5	27.1	30.6
Ibuprofen	1.32 ± 0.03	40.0	100	-	-
Diclofenac	1.24 ± 0.03	43.6	-	100	-
Ketorolac	1.35 ± 0.04	38.6	-	-	100

Note: *SEM denotes the standard error of the mean

well-recognized anti-inflammatory and analgesic agents [20–24]. There are many reports that the incorporation of fluorine into a molecule results in increased binding affinity to the target protein [25–29]. In addition, an increase in the rate of absorption and transport of the drug *in vivo* was observed [27–29].

The consensus values for lipophilicity and water solubility [30] calculated using the Swiss-ADME web resource [31] correlate with the anti-inflammatory activity of highly active fluorinated compounds (**Figure 1**). An increase in lipophilicity and a decrease in solubility lead to the loss of the anti-inflammatory effect. It should be noted that fluoro-substituted derivatives are also among the anti-inflammatory drugs available in the pharmaceutical market (Celecoxib, Fluproquazone).

Cyclooxygenase (COX) enzymes are involved in the synthesis of various prostanoids, which participate in physiological and pathological mechanisms of inflammation. There are two isoforms of COX enzymes: COX-1 and COX-2. COX-1 is a regulatory enzyme with physiological and homeostatic functions, whereas COX-2 stimulates the synthesis of prostaglandins, which cause pathological conditions, such as inflammation. Side effects of NSAIDs are caused by the inhibition of the physiological function of COX-1, while selective COX-2 inhibitors cause the anti-inflammatory activity without the risk of side effects. Compounds **3b–d** were docked [32, 33] into the binding site pockets of COX-1 and COX-2. The molecular docking studies were conducted using Autodock Vina [32] for docking simulations and a Discovery Studio Visualizer [33] for visualization

and interpretation. The protein structures were retrieved from the Protein Data Bank (PDB): Cyclooxygenase 2 (PDB ID 1PXX) and Cyclooxygenase 1 (PDB ID 1HT5). Proteins were prepared by removing water molecules, adding hydrogen atoms, assigning partial charges, and converting the protein to the PDBQT format using AutoDock Tools. Ligands were drawn using ChemDraw and prepared by adding hydrogens, assigning charges, and optimizing their geometry through the energy minimization using Open Babel, then converted to the PDBQT format. AutoDock Vina was then utilized to perform the docking simulation, with a grid box size of 20 Å defined to encompass the protein's active site and an exhaustiveness value of 8 to ensure a thorough search. A Discovery Studio Visualizer was used to visualize and analyze the docked complexes, identifying key interactions.

These compounds exhibited stronger interactions at the COX-2 binding site than the COX-1 active site pocket. Binding scores and information about amino acids involved in interactions of the docked compounds **3b–d** on the active sites of COX-1 and COX-2 enzymes are provided in **Table 2** and visualized in **Figures 2–4**.

Compounds **3b–d** are characterized by Pi-Sigma and Pi-Alkyl interactions of amino acid fragments, which contain alkyl residues with aromatic cycles or a heterocyclic system (**Table 2**). In addition, an important role in bonding is played by Pi-Cation, Pi-Sulfur, Pi-Pi Stacked, Pi-Pi T-shaped, and various hydrogen bonds. (Conventional Hydrogen Bond, Carbon Hydrogen Bond, Pi-Donor Hydrogen Bond) (**Table 2**).






Figure 1. Bioactive fluorinated compounds **3b–d** and anti-inflammatory drugs


Compound 3b
COX-1



Interactions



Compound 3b
COX-2



Interactions






Figure 2. The binding mode of compound 3b into the binding sites of COX-1 and COX-2


Compound 3c
COX-1



Interactions



Compound 3c
COX-2



Interactions






Figure 3. The binding mode of compound 3c into the binding sites of COX-1 and COX-2


Compound 3d
COX-1



Interactions



Compound 3d
COX-2



Interactions




Figure 4. The binding mode of compound 3d into the binding sites of COX-1 and COX-2

Table 2. Binding scores and amino acids involved in interactions of the docked compounds **3b-d** on the active sites of COX-1 and COX-2 enzymes*

Compound	Binding energy, kcal mol ⁻¹		Interacting residues			
			Conventional Hydrogen Bond, Carbon Hydrogen Bond, Pi-Donor Hydrogen Bond	Pi-Cation, Pi-Sulfur	Pi-Pi Stacked, Pi-Pi T-shaped	Pi-Alkyl, Pi-Sigma
3b	COX-1	-7.4	Arg B:88 Tyr B:323 Ser B:498	Arg B:88 Tyr B:323	Tyr B:323	Leu B:499 Val B:317 Ile B:57 Leu B:61 Val B:84 Ala B: 495
	COX-2	-9.6	Ser A:499 Phe A:487	–	–	Ala A:496 Val A:85 Val A:318 Val A:492 Leu A:328 Leu A:321 Ala A:485 His A:58 Leu A:500 Ala A:496 Val A:318 Val A:492
3c	COX-1	-7.5	Tyr B:323 Ser B:321 Ser B:498	Phe B:486	Tyr B:323 Trp B:355	Val B:84 Val B:317 Ala B: 495 Leu B:320 Leu B:499 Ile B:491
	COX-2	-8.8	Tyr A:324	–	Trp A:356	Leu A:321 Val A:318 Val A:492 Ala A:496 Leu A:328 Val A:85 Leu A:500
3d	COX-1	-6.6	Arg B:88	Tyr B:323	Tyr B:323	Leu B:61 Ile B:57 Val B:84 Leu B:499 Val B:317 Leu B:61 Ile B:57 Val B:84 Ala B:495
	COX-2	-8.9	Gln A:161	–	–	Val A:318 Ala A:496 Leu A:328 Val A:492 Phe A:487 His A:58 Ala A:485 Leu A:500 Val A:318 Ser A:322 Val A:492

Note: *Colors of the amino acids involved in the interactions correspond to those shown in Figures 2-4

The calculated binding energy of compounds **3b–d** is similar to the binding energy for such non-steroidal anti-inflammatory drugs as Ibuprofen, Diclofenac, Ketorolac, and Celecoxib. The selectivity of binding to cyclooxygenases was not observed (Table 3).

Conclusions

In order to develop new effective anti-inflammatory agents, a series of [1,2,4]triazolo[3,4-*b*]-[1,3,4]thiadiazoles has been synthesized. Among them, 3-(2-fluorophenyl)-6-phenyl-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (**3c**) and 3-(2-fluorophenyl)-6-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (**3d**) have shown the best activity.

Experimental part

The ¹H NMR spectra presented in this work were obtained on a Varian instrument at an operating frequency of 400 MHz with DMSO-*d*₆ as a solvent and tetramethylsilane as an internal standard. Elemental analyses were performed using a Carlo Erba 1106 instrument. Melting points were determined on a Boetius melting point apparatus.

4-Amino-5-(4-*R*-benzyl)-4*H*-[1,2,4]triazol-3-thiols **1a,b** were obtained according to the procedure described in [34].

The general procedure for the synthesis of [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole derivatives 3a–f

The corresponding 4-amino-5-*R*-4*H*-[1,2,4]triazol-3-thiol **1a–d** (5 mmol) and benzoic acids **2a–d** (5 mmol) were dissolved in POCl₃ (10 mL). The reaction mixture was refluxed for 8 h, cooled to room temperature, and poured into a mixture of NaOH (20 g), water (50 mL), and ice (50 g). In 1 hour, the precipitate was filtered off and recrystallized from an ethanol-DMFA mixture giving light yellow powders.

3,6-Diphenyl-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (3a)

Yield – 75 %. M. p. 159–160 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm: 7.81–7.48 (6H, m, ArH), 8.07 (2H, d, *J* = 7.1 Hz, ArH), 8.32 (2H, d,

J = 7.3 Hz, ArH). Anal. Calcd for C₁₅H₁₀N₄S, %: C 64.73, H 3.62, N 20.13. Found, %: C 64.77, H 3.72, N 20.20.

3-Phenyl-6-(4-trifluoromethylphenyl)-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (3b)

Yield – 87 %. M. p. 188–200 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm: 7.82–7.47 (3H, m, ArH), 8.02 (2H, d, *J* = 8.2 Hz, ArH), 8.26–8.34 (4H, m, ArH). Anal. Calcd for C₁₆H₉F₃N₄S, %: C 55.49, H 2.62, N 16.18. Found, %: C 55.62, H 2.73, N 16.22.

3-(2-Fluorophenyl)-6-phenyl-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (3c)

Yield – 84%. M. p. 175–176 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm: 7.53–7.44 (2H, m, ArH), 7.61 (2H, t, *J* = 7.7 Hz, ArH), 7.71–7.64 (2H, m, ArH), 7.97 (2H, d, *J* = 8.0 Hz, ArH), 8.07 (1H, t, *J* = 7.5 Hz, ArH). Anal. Calcd for C₁₅H₉FN₄S, %: C 60.80, H 3.06, N 18.91. Found, %: C 60.75, H 2.99, N 18.70.

3-(2-Fluorophenyl)-6-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (3d)

Yield – 81 %. M. p. 181–183 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm: 3.85 (3H, s, CH₃O), 7.14 (2H, d, *J* = 7.4 Hz, ArH), 7.56–7.41 (2H, m, ArH), 7.67 (1H, d, *J* = 6.2 Hz, ArH), 7.92 (2H, d, *J* = 7.3 Hz, ArH), 8.06 (1H, t, *J* = 7.5 Hz, ArH). Anal. Calcd for C₁₆H₁₁FN₄OS, %: C 58.89, H 3.40, N 17.17. Found, %: 58.95, H 3.45, N 17.10.

3-(4-Chlorobenzyl)-6-phenyl-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (3e)

Yield – 71 %. M. p. 192–193 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm: 4.47 (2H, s, CH₂), 7.40 (4H, s, ArH), 7.60–7.72 (2H, m, ArH), 7.93 (2H, d, *J* = 6.7 Hz, ArH). Anal. Calcd for C₁₆H₁₁ClN₄S, %: C 58.81, H 3.39, N 17.14. Found, %: 58.69, H 3.44, N 17.21.

6-(3,4-Dimethoxyphenyl)-3-(4-methoxybenzyl)-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole (3f)

Yield – 72 %. M. p. 201–202 °C. ¹H NMR (400 MHz, DMSO-*d*₆), δ, ppm: 3.70 (3H, s, CH₃O), 3.85 (3H, s, CH₃O), 3.86 (3H, s, CH₃O), 4.36 (2H, s), 6.88 (2H, d, *J* = 8.6 Hz, ArH), 7.14 (1H, d, *J* = 8.5 Hz, ArH), 7.30 (2H, d, *J* = 8.5 Hz, ArH), 7.37 (1H, d, *J* = 1.9 Hz, ArH), 7.48 (1H, dd, *J* = 8.4, 2.0 Hz, ArH). Anal. Calcd for C₁₉H₁₈N₄O₃S, %: C 59.67, H 4.74, N 14.65. Found, %: 59.79, H 4.61, N 14.54.

Table 3. The binding energy, kcal mol⁻¹ of the docked compounds **3b–d** and Ibuprofen, Diclofenac, Ketorolac, and Celecoxib on the active sites of COX-1 and COX-2 enzymes

Target protein	Compound						
	3b	3c	3d	Ibuprofen	Diclofenac	Ketorolac	Celecoxib
COX-1	-7.4	-7.5	-6.6	-7.6	-7.7	-8.6	-5.2
COX-2	-9.6	-8.8	-8.9	-7.4	-8.4	-8.7	-10.2

The method for studying the anti-inflammatory activity *in vivo* [19]

All *in vivo* procedures on animals comply with the standards of the European Convention for the Protection of Vertebrate Animals Used for Research and Scientific Purposes (Strasbourg, 1985), the Council Directive 2010/63/EU and the Law of Ukraine No. 3447-IV “On the Protection of Animals from Cruelty” as amended by 440-IX of 14.01.2020.

We conducted a study of the anti-inflammatory activity using the method of carrageenan-induced paw edema in rats. White Wistar rats weighing 180-250 g were used for this study. The laboratory animals were divided into 10 groups. Each group consisted of 5 rats. To test the anti-inflammatory activity of 6 compounds synthesized and 3 reference drugs (Ibuprofen, Diclofenac and Ketorolac), in total, 9 experimental groups were used, and the 10th test group was the control group.

The compounds studied (50 mg/kg of the body weight) and Ibuprofen, Diclofenac, Ketorolac in the mean therapeutic dose (10 mg/kg of the body weight) were dissolved in DMSO and administered intraperitoneally. Only DMSO was administered

to the animals from the control group. In 1 hour, a generalized edema was induced by injecting 0.1 mL of 2% carrageenan solution under aseptic conditions under the aponeurosis of the rat hindlimb sole. The inflammatory response was determined by the change in the limb volume using the oncometric method at the beginning of the experiment and 4 hours after administration of the phlogogenic agent. The inhibition of the inflammatory response was calculated as a percentage of the reduction in the paw volume using the following formula:

$$\% \text{ Inhibition} = \frac{V_{\text{control}} - V}{V_{\text{control}}} \times 100 \%$$

where V_{control} is the increase in the paw volume in the control group of animals;

V is the increase in the paw volume in animals injected with the test substances.

■ Acknowledgments

The author thanks Prof. Pinyazhko O. R. and researcher Nektegayev I. O. for their efforts in performing the *in vivo* biological screening.

■ References

- Gusev, E.; Zhuravleva, Y. Inflammation: A New Look at an Old Problem. *Int. J. Mol. Sci.* **2022**, *23*, 4596. <https://doi.org/10.3390/ijms23094596>.
- Tai, F. W. D.; McAlindon, M. E. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. *Clinical Medicine* **2021**, *21* (2), 131–134. <https://doi.org/10.7861/clinmed.2021-0039>.
- Mitsis, A.; Avraamides, P.; Lakoumentas, J.; Kyriakou, M.; Sokratous, S.; Karmioti, G.; Drakomathoulakis, M.; Theodoropoulos, K. C.; Nasoufidou, A.; Evangelidou, A.; Vassilikos, V.; Fragakis, N.; Ziakas, A.; Tzikas, S.; Kassimis, G. Role of Inflammation Following An Acute Myocardial Infarction: Design of INFINITY. *Biomarkers in Medicine*. **2023**, *17* (23), 971–981. <https://doi.org/10.2217/bmm-2023-0491>.
- Aggarwal, R.; Sumran, G. An insight on medicinal attributes of 1,2,4-triazoles. *Eur. J. Med. Chem.* **2020**, *205*, 112652. <https://doi.org/10.1016/j.ejmech.2020.112652>.
- Bozorov, K.; Zhao, J.; Aisa, H. A. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview. *Bioorg. Med. Chem.* **2019**, *27* (16), 3511–3531. <https://doi.org/10.1016/j.bmc.2019.07.005>.
- Iraji, A.; Firuzi, O.; Khoshneviszadeh, M.; Tavakkoli, M.; Mahdavi, M.; Nadri, H.; Edraki, N.; Miri, R. Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease. *Eur. J. Med. Chem.* **2017**, *141*, 690–702. <https://doi.org/10.1016/j.ejmech.2017.09.057>.
- Li, Y.; Geng, J.; Liu, Y.; Yu, S.; Zhao, G. Thiadiazole—a Promising Structure in Medicinal Chemistry. *ChemMedChem*. **2013**, *8* (1), 27–41. <https://doi.org/10.1002/cmdc.201200355>.
- Khalili Ghomi, M.; Noori, M.; Nazari Montazer, M.; Zomorodian, K.; Dastyafteh, N.; Yazdanpanah, S.; Sayahi, M. H.; Javanshir, S.; Nouri, A.; Asadi, M.; Badali, H.; Larijani, B.; Iraji, C.; Iraji, A.; Mahdavi, M. [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as new therapeutic candidates against urease positive microorganisms: design, synthesis, pharmacological evaluations, and in silico studies. *Scientific reports* **2023**, *13* (1), 10136. <https://doi.org/10.1038/s41598-023-37203-z>.
- Mathew, V.; Keshavayya, J.; Vaidya, V. P.; Giles, D. Studies on synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues. *Eur. J. Med. Chem.* **2007**, *42* (6), 823–840. <https://doi.org/10.1016/j.ejmech.2006.12.010>.
- Gilani, S. J.; Khan, S. A.; Siddiqui, N. Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives of isoniazid. *Bioorg. Med. Chem. Lett.* **2010**, *20* (16), 4762–4765. <https://doi.org/10.1016/j.bmcl.2010.06.125>.
- Zhang, L.; Zhao, J.; Zhang, B.; Lu, T.; Chen, Y. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity. *Eur. J. Med. Chem.* **2018**, *150*, 809–816. <https://doi.org/10.1016/j.ejmech.2018.03.049>.
- Chidananda, N.; Poojary, B.; Sumangala, V.; Kumari, N. S.; Shetty, P.; Arulmoli, T. Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]-thiadiazoles. *Eur. J. Med. Chem.* **2012**, *51*, 124–136. <https://doi.org/10.1016/j.ejmech.2012.02.030>.
- Al-Wahaibi, L. H.; Karthikeyan, S.; Blacque, O.; El-Masry, A. A.; Hassan, H. M.; Percino, M. J.; El-Emam, A. A.; Thamocharan, S. Structural and Energetic Properties of Weak Noncovalent Interactions in Two Closely Related 3,6-Disubstituted-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole Derivatives: *In Vitro* Cyclooxygenase Activity, Crystallography, and Computational Investigations. *ACS Omega* **2022**, *7* (38), 34506–34520. <https://doi.org/10.1021/acsomega.2c04252>.

14. Maddila, S.; Gorle, S.; Singh, M.; Lavanya, P.; Jonnalagadda, S. B. Synthesis and Anti-Inflammatory Activity of Fused 1,2,4-triazolo-[3,4-b] [1,3,4]thiadiazole Derivatives of Phenothiazine. *Letters in Drug Design & Discovery* **2013**, *10* (10), 977–983. <http://dx.doi.org/10.2174/15701808113109990034>.
15. Birsen, T.; Sevim Peri, A.; Sule, G.; Selami, G.; Goknur, A. Novel 1,2,4-Triazolo[3,4-b]-1,3,4-thiadiazole Derivatives as Dual Analgesic/Anti-inflammatory and Antimicrobial Agents. *Letters in Drug Design & Discovery* **2012**, *9* (2), 204–212. <http://dx.doi.org/10.2174/157018012799079626>.
16. Apan, A.; Casoni, D.; Leonte, D.; Pop, C.; Iaru, I.; Mogoşan, C.; Zaharia, V. Heterocycles 52: The Drug-Likeness Analysis of Anti-Inflammatory Thiazolo[3,2-b][1,2,4]triazole and Imidazo[2,1-b][1,3,4]thiadiazole Derivatives. *Pharmaceuticals* **2024**, *17*, 295. <https://doi.org/10.3390/ph17030295>.
17. Pathak, P.; Shukla, P. K.; Naumovich, V.; Grishina, M.; Verma, A.; Potemkin, V. 1,2,4-Triazole-conjugated 1,3,4-thiadiazole hybrid scaffolds: A potent ameliorant of carrageenan-induced inflammation by lessening proinflammatory mediators. *Arch. Pharm.* **2020**, *353* (1), 1900233. <https://doi.org/10.1002/ardp.201900233>.
18. Tratat, C.; Haroun, M.; Papisisva, A.; Kamoutsis, C.; Petrou, A.; Gavalas, A.; Eleftheriou, P.; Geronikaki, A.; Venugopala, K.N.; Kochkar, H.; et al. New Substituted 5-Benzylideno-2-Adamantylthiazol[3,2-b][1,2,4]Triazol-6(5H)ones as Possible Anti-Inflammatory Agents. *Molecules* **2021**, *26*, 659. <https://doi.org/10.3390/molecules26030659>.
19. Atta-ur-Rahman; Choudhary, M. I.; Thomsen, W. J. *Bioassay techniques for drug development*. Harwood academic Publishers, 2005, 203 p.
20. Chawla, G.; Kumar, U.; Bawa, S.; Kumar, J. Syntheses and evaluation of anti-inflammatory, analgesic and ulcerogenic activities of 1,3,4-oxadiazole and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole derivatives. *J. Enzyme Inhib. Med. Chem.* **2012**, *27* (5), 658–665. <https://doi.org/10.3109/14756366.2011.606543>.
21. Luan, M. Z.; Zhang, X. F.; Yang, Y.; Meng, Q. G.; Hou, G. G. Anti-inflammatory activity of fluorine-substituted benzo[h]quinazoline-2-amine derivatives as NF-κB inhibitors. *Bioorg. Chem.* **2023**, *132*, 106360. <https://doi.org/10.1016/j.bioorg.2023.106360>.
22. Kalkhambkar, R. G.; Kulkarni, G. M.; Kamanavalli, C. M.; Premkumar, N.; Asdaq, S. M.; Sun, C. M. Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins. *Eur. J. Med. Chem.* **2008**, *43* (10), 2178–2188. <https://doi.org/10.1016/j.ejmech.2007.08.007>.
23. Kaur, K.; Kumar, V.; Gupta, G. K. Trifluoromethylpyrazoles as anti-inflammatory and antibacterial agents: A review. *J. Fluor. Chem.* **2015**, *178*, 306–326. <https://doi.org/10.1016/j.jfluchem.2015.08.015>.
24. Nargund, L. V.; Hariprasad, V.; Reedy, G. R. Synthesis and anti-inflammatory activity of fluorinated phenyl styryl ketones and N-phenyl-5-substituted aryl-3-p-(fluorophenyl) pyrazolins and pyrazoles. *J. Pharm. Sci.* **1992**, *81* (9), 892–894. <https://doi.org/10.1002/jps.2600810910>.
25. Ali, S.; Bolinger, A. A.; Zhou, J. Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023. *Curr. Top. Med. Chem.* **2024**, *24* (10), 843–849. <https://doi.org/10.2174/0115680266300245240223070242>.
26. Wang, Q.; Bian, Y.; Dhawan, G.; Zhang, W.; Sorochinsky, A. E.; Makarem, A.; Soloshonok, V. A.; Han J. FDA approved fluorine-containing drugs in 2023. *Chin. Chem. Lett.* **2024**, *35* (11), 109780, <https://doi.org/10.1016/j.ccllet.2024.109780>.
27. Sheikhi, N.; Bahraminejad, M.; Saeedi, M.; Mirfazli, S. S. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022. *Eur. J. Med. Chem.* **2023**, *260*, 115758. <https://doi.org/10.1016/j.ejmech.2023.115758>.
28. Chandra, G.; Singh, D. V.; Mahato, G. K.; Patel, S. Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs. *Chemical Papers* **2023**, *77* (8), 4085–4106. <https://doi.org/10.1007/s11696-023-02804-5>.
29. Henary, E.; Casa, S.; Dost, T.L.; Sloop, J.C.; Henary, M. The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications. *Pharmaceuticals* **2024**, *17*, 281. <https://doi.org/10.3390/ph17030281>.
30. Delaney, J. S. ESOL: estimating aqueous solubility directly from molecular structure. *J. Chem. Inf. Comput. Sci.* **2004**, *44* (3), 1000–1005. <https://doi.org/10.1021/ci034243x>.
31. SwissADME. <http://www.swissadme.ch/index.php> (accessed Sep 13, 2024).
32. Autodock Vina. <https://vina.scripps.edu/> (accessed Jun 21, 2024).
33. Discovery Studio. <https://discover.3ds.com/discovery-studio-visualizer-download> (accessed Jun 26, 2024).
34. Kamboj, V. K.; Kapoor, A.; Jain, S. Synthesis, Antimicrobial, and Antioxidant Screening of Aryl Acetic Acid Incorporated 1,2,4-Triazolo-1,3,4-Thiadiazole Derivatives. *J. Heterocycl. Chem.* **2019**, *56* (4), 1376–1382. <https://doi.org/10.1002/jhet.3513>.

Information about the author:

Iryna I. Myrko (corresponding author), Assistant Professor, Department of General, Bioinorganic, Physico-colloid Chemistry, Danylo Halatsky Lviv National Medical University; <https://orcid.org/0000-0003-3979-543X>; e-mail for correspondence: irynaoliinyk@gmail.com.